AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38977653 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 0
Study 38977655 — intervention group
Group type: EXPERIMENTAL
Intervention: High John Henryism (JH)
Number of subjects: 274
Study 38977655 — intervention group
Group type: COMPARATOR
Intervention: Low John Henryism (JH)
Number of subjects: 274
Study 38977707 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd)
Number of subjects: 0
Study 38977707 — intervention group
Group type: COMPARATOR
Intervention: RVd (control group)
Number of subjects: 0
Study 38977715 — intervention group
Group type: EXPERIMENTAL
Intervention: Short mutated allele (40-45 CAG repeats) with normal alleles more than 17 CAG repeats
Number of subjects: 3723
Study 38977715 — intervention group
Group type: EXPERIMENTAL
Intervention: Short mutated allele (40-45 CAG repeats)
Number of subjects: 3723
Study 38977715 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal alleles in higher half of length distribution (more than 17 CAG repeats)
Number of subjects: 3723
Study 38977914 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental MRI
Number of subjects: 0
Study 38977914 — intervention group
Group type: COMPARATOR
Intervention: Traditional breast density measures
Number of subjects: 0
Study 38977983 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hyperglycemia (defined as ≥ 6.1mmol/L)
Number of subjects: 1440
Study 38977983 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative glucose levels as a continuous variable
Number of subjects: 1440
Study 38977983 — intervention group
Group type: COMPARATOR
Intervention: Normal preoperative glucose levels
Number of subjects: 1440
Study 38977995 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face traditional training group (TRHG)
Number of subjects: 75
Study 38977995 — intervention group
Group type: EXPERIMENTAL
Intervention: General remote training group (GTHG)
Number of subjects: 75
Study 38977995 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based remote training group (AITHG)
Number of subjects: 75
Study 38978009 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary medication review using STOPP criteria
Number of subjects: 674
Study 38978009 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary medication review using START criteria
Number of subjects: 674
Study 38978009 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical committee decisions on STOPP criteria
Number of subjects: 674
Study 38978009 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical committee decisions on START criteria
Number of subjects: 674
Study 38978010 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2D) patients
Number of subjects: 84
Study 38978010 — intervention group
Group type: EXPERIMENTAL
Intervention: RNAseq analysis
Number of subjects: 84
Study 38978010 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional enrichment analysis
Number of subjects: 84
Study 38978010 — intervention group
Group type: EXPERIMENTAL
Intervention: Downregulated gene sets
Number of subjects: 84
Study 38978051 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation alone (O)
Number of subjects: 38
Study 38978051 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery with action observation (OI)
Number of subjects: 38
Study 38978051 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor execution synchronized with action observation (OM)
Number of subjects: 38
Study 38978051 — intervention group
Group type: COMPARATOR
Intervention: Control (C) - Passive observation
Number of subjects: 38
Study 38978068 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LUS aeration score
Number of subjects: 442
Study 38978068 — intervention group
Group type: EXPERIMENTAL
Intervention: Early deterioration of the LUS score
Number of subjects: 442
Study 38978068 — intervention group
Group type: EXPERIMENTAL
Intervention: Early change in the LUS aeration score
Number of subjects: 442
Study 38978065 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal testing and treatment (UTT) intervention
Number of subjects: 1499
Study 38978065 — intervention group
Group type: EXPERIMENTAL
Intervention: Working as a community health worker (CHW)
Number of subjects: 1499
Study 38978065 — intervention group
Group type: EXPERIMENTAL
Intervention: Witnessing stigmatizing behaviors towards people living with HIV among co-workers
Number of subjects: 1499
Study 38978065 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher educational attainment
Number of subjects: 1499
Study 38978065 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater years providing HIV services
Number of subjects: 1499
Study 38978065 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing negative for HIV at last HIV test
Number of subjects: 1499
Study 38978089 — intervention group
Group type: EXPERIMENTAL
Intervention: Decolonization with octenisan® wash lotion 1× per day and octenisan® md nasal gel 2-3× per day for 5 days
Number of subjects: 1000
Study 38978089 — intervention group
Group type: COMPARATOR
Intervention: No decolonization (Control)
Number of subjects: 1000
Study 38978089 — intervention group
Group type: EXPERIMENTAL
Intervention: Decolonization
Number of subjects: 1000
Study 38978119 — intervention group
Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling (FSN) therapy, 3 times a week for 2 weeks
Number of subjects: 60
Study 38978119 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib, 0.2 g/day oral for 2 weeks
Number of subjects: 60
Study 38978119 — intervention group
Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling (FSN) therapy
Number of subjects: 60
Study 38978117 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio-Metabolic Clinic treatment
Number of subjects: 1500
Study 38978117 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1500
Study 38978124 — intervention group
Group type: EXPERIMENTAL
Intervention: CATT
Number of subjects: 1095
Study 38978124 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT Sero-K-SeT
Number of subjects: 1095
Study 38978124 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioline HAT 2.0
Number of subjects: 1095
Study 38978124 — intervention group
Group type: EXPERIMENTAL
Intervention: DCN HAT RDT
Number of subjects: 1095
Study 38978124 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT Sero-K-SeT 2.0
Number of subjects: 1095
Study 38978124 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunological laboratory tests
Number of subjects: 1095
Study 38978124 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular laboratory tests
Number of subjects: 1095
Study 38978124 — intervention group
Group type: COMPARATOR
Intervention: Abbott Bioline HAT 2.0
Number of subjects: 1095
Study 38978124 — intervention group
Group type: COMPARATOR
Intervention: HAT Sero-K-Set 2.0
Number of subjects: 1095
Study 38978309 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors/ARBs use
Number of subjects: 269
Study 38978309 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 269
Study 38978309 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher haemoglobin
Number of subjects: 269
Study 38978309 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HbF
Number of subjects: 269
Study 38978309 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 269
Study 38978309 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher alkaline phosphatase
Number of subjects: 269
Study 38978354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin 10%
Number of subjects: 44
Study 38978405 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB+RPV LA administered every 2 months (Q2M)
Number of subjects: 70
Study 38978405 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB+RPV LA
Number of subjects: 70
Study 38978405 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (Arm-S)
Number of subjects: 70
Study 38978405 — intervention group
Group type: COMPARATOR
Intervention: Enhanced arm (Arm-E)
Number of subjects: 70
Study 38978403 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF/emtricitabine (FTC)/DTG
Number of subjects: 0
Study 38978403 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil fumarate (TDF)/FTC/DTG
Number of subjects: 0
Study 38978403 — intervention group
Group type: COMPARATOR
Intervention: TDF/FTC/efavirenz (EFV)
Number of subjects: 0
Study 38978512 — intervention group
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine (second dose administered at enrollment, day 1)
Number of subjects: 146
Study 38978512 — intervention group
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine (first dose administered ≥1 year before enrollment)
Number of subjects: 146
Study 38978512 — intervention group
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine (adverse events reported through 15 days after vaccination)
Number of subjects: 146
Study 38978573 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized behavioral approach for dietary management
Number of subjects: 255
Study 38978573 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized behavioral intervention (one-size-fits-all dietary recommendations)
Number of subjects: 255
Study 38978573 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (UCC)
Number of subjects: 255
Study 38978597 — intervention group
Group type: COMPARATOR
Intervention: Routine supplementation (400 IU/day with established feedings)
Number of subjects: 180
Study 38978597 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased supplementation (800 IU/day with any feedings)
Number of subjects: 180
Study 38978605 — intervention group
Group type: EXPERIMENTAL
Intervention: AMBLE training (dorsiflexion assist-as-needed ankle robotics) for 9 hours (9 weeks × 2 sessions/week)
Number of subjects: 16
Study 38978605 — intervention group
Group type: EXPERIMENTAL
Intervention: AMBLE training
Number of subjects: 16
Study 38978659 — intervention group
Group type: EXPERIMENTAL
Intervention: Household contact investigation (HCI)
Number of subjects: 39
Study 38978673 — intervention group
Group type: EXPERIMENTAL
Intervention: IV GD2-CART (DL1=1e6/kg; DL2=3e6/kg) followed by ICV GD2-CART (10-30e6 GD2-CART)
Number of subjects: 11
Study 38978673 — intervention group
Group type: COMPARATOR
Intervention: IV GD2-CART (DL2=3e6/kg)
Number of subjects: 11
Study 38978673 — intervention group
Group type: EXPERIMENTAL
Intervention: ICV GD2-CART infusions
Number of subjects: 11
Study 38978809 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Number of subjects: 200
Study 38978809 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 200
Study 38978814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac-related spinal cord motion measurements in MRI+ patients
Number of subjects: 84
Study 38978814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac-related spinal cord motion measurements in MRI- patients
Number of subjects: 84
Study 38978814 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of spinal stenosis (aSCOR)
Number of subjects: 84
Study 38979062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil (≥4 consecutive intravenous doses)
Number of subjects: 132
Study 38979073 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa group
Number of subjects: 68
Study 38979073 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 68
Study 38979073 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysical therapy (received by 73% of AN participants)
Number of subjects: 68
Study 38979608 — intervention group
Group type: EXPERIMENTAL
Intervention: ARRY-371797
Number of subjects: 77
Study 38979608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 38979716 — intervention group
Group type: COMPARATOR
Intervention: Ibandronate
Number of subjects: 35163
Study 38979716 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 35163
Study 38979716 — intervention group
Group type: COMPARATOR
Intervention: Risedronate
Number of subjects: 35163
Study 38979716 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 35163
Study 38979716 — intervention group
Group type: COMPARATOR
Intervention: Clodronate
Number of subjects: 35163
Study 38979716 — intervention group
Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 35163
Study 38979716 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate
Number of subjects: 35163
Study 38979743 — intervention group
Group type: COMPARATOR
Intervention: Non-oxygenated hypothermic machine perfusion (HMP)
Number of subjects: 4007
Study 38979743 — intervention group
Group type: COMPARATOR
Intervention: Continuous non-oxygenated HMP
Number of subjects: 4007
Study 38979743 — intervention group
Group type: COMPARATOR
Intervention: Oxygenated continuous HMP
Number of subjects: 4007
Study 38979743 — intervention group
Group type: COMPARATOR
Intervention: End-ischaemic NMP (one hour)
Number of subjects: 4007
Study 38979756 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-303 18 mg
Number of subjects: 231
Study 38979756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 38979812 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 3231
Study 38979812 — intervention group
Group type: COMPARATOR
Intervention: Best medical management
Number of subjects: 3231
Study 38979830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebral hemorrhage patients with anemia development
Number of subjects: 563
Study 38979830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebral hemorrhage patients with systemic inflammatory response syndrome (SIRS)
Number of subjects: 563
Study 38979830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebral hemorrhage patients with hemoglobin changes
Number of subjects: 563
Study 38979893 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 309
Study 38979893 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 309
Study 38980082 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized hyaluronic acid (HA) spacer
Number of subjects: 136
Study 38980207 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 0
Study 38980272 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (3-5 days)
Number of subjects: 527
Study 38980272 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (1-2 days)
Number of subjects: 527
Study 38980329 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR-guided delayed revascularization
Number of subjects: 202
Study 38980329 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided delayed revascularization
Number of subjects: 202
Study 38980511 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue injection
Number of subjects: 9
Study 38980664 — intervention group
Group type: EXPERIMENTAL
Intervention: D2+No.10 group (sLNR ≤0.4)
Number of subjects: 733
Study 38980664 — intervention group
Group type: COMPARATOR
Intervention: D2 group (sLNR ≤0.4)
Number of subjects: 733
Study 38980666 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized targeted heart rate aerobic exercise (n = 102)
Number of subjects: 198
Study 38980666 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention designed to mimic relative rest (n = 96)
Number of subjects: 198
Study 38980678 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel interventions including electronic medical record changes and oral health education and skills training
Number of subjects: 1023
Study 38980678 — intervention group
Group type: COMPARATOR
Intervention: AAP-based standard oral health education
Number of subjects: 1023
Study 38980676 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) with orteronel, 300 mg orally twice daily
Number of subjects: 1279
Study 38980676 — intervention group
Group type: COMPARATOR
Intervention: AD therapy with bicalutamide, 50 mg orally daily
Number of subjects: 1279
Study 38980675 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioral Therapy for Insomnia (eCBT-I) delivered over 6 weekly lesson modules with assigned homework activities.
Number of subjects: 125
Study 38980675 — intervention group
Group type: COMPARATOR
Intervention: Online sleep education (control group).
Number of subjects: 125
Study 38980675 — intervention group
Group type: EXPERIMENTAL
Intervention: eCBT-I group outcomes correlated with improvements in depression symptoms, PTSD symptoms, sleep quality, and fatigue impact.
Number of subjects: 125
Study 38980710 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-based self-management app (selfBACK) as an adjunct to usual care
Number of subjects: 99
Study 38980710 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 99
Study 38980725 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab with ART
Number of subjects: 0
Study 38980968 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol, 100,000 IU, five doses in 3 months)
Number of subjects: 88
Study 38980968 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 88
Study 38980968 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (open-label, 100,000 IU/month for 6 months)
Number of subjects: 88
Study 38980968 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 88
Study 38980968 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole group (both EG and CG)
Number of subjects: 88
Study 38981063 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain survivors (N = 96; 41% of total)
Number of subjects: 233
Study 38981063 — intervention group
Group type: COMPARATOR
Intervention: Previous intravenous methotrexate treatment
Number of subjects: 233
Study 38981063 — intervention group
Group type: COMPARATOR
Intervention: Respiratory chronic health conditions
Number of subjects: 233
Study 38981063 — intervention group
Group type: COMPARATOR
Intervention: Gastrointestinal chronic health conditions
Number of subjects: 233
Study 38981063 — intervention group
Group type: COMPARATOR
Intervention: Neurological chronic health conditions
Number of subjects: 233
Study 38981063 — intervention group
Group type: COMPARATOR
Intervention: Unemployment
Number of subjects: 233
Study 38981063 — intervention group
Group type: COMPARATOR
Intervention: Clinically significant depression and anxiety
Number of subjects: 233
Study 38981063 — intervention group
Group type: COMPARATOR
Intervention: Diagnosis of childhood Ewing sarcoma or osteosarcoma
Number of subjects: 233
Study 38981063 — intervention group
Group type: COMPARATOR
Intervention: Cardiovascular and neurological conditions, unemployment, clinical levels of depression and/or anxiety, fear of cancer recurrence
Number of subjects: 233
Study 38981063 — intervention group
Group type: COMPARATOR
Intervention: Low sleep quality, elevated anxiety, and elevated depression (for male survivors)
Number of subjects: 233
Study 38981119 — intervention group
Group type: EXPERIMENTAL
Intervention: Living Donor Digital Care Path
Number of subjects: 127
Study 38981590 — intervention group
Group type: EXPERIMENTAL
Intervention: GWO+RuleFit
Number of subjects: 0
Study 38981665 — intervention group
Group type: EXPERIMENTAL
Intervention: High-illuminance (10k lux)
Number of subjects: 81
Study 38981665 — intervention group
Group type: COMPARATOR
Intervention: Low-illuminance (4k lux)
Number of subjects: 81
Study 38981881 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy (LDG)
Number of subjects: 446
Study 38981881 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 446
Study 38981954 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA coadministered with FLU-QIV-HD
Number of subjects: 1029
Study 38981954 — intervention group
Group type: COMPARATOR
Intervention: FLU-QIV-HD alone followed by RSVPreF3 OA at a separate visit 1 month later
Number of subjects: 1029
Study 38981994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with PGP
Number of subjects: 125
Study 38981994 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women without PGP
Number of subjects: 125
Study 38981994 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 125
Study 38981994 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiophobia
Number of subjects: 125
Study 38981994 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Image (BI)
Number of subjects: 125
Study 38982000 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled xenon combined with target temperature management (33 °C) for 24 hours
Number of subjects: 110
Study 38982000 — intervention group
Group type: COMPARATOR
Intervention: Target temperature management alone
Number of subjects: 110
Study 38982000 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 38981998 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution TEMPURA
Number of subjects: 24
Study 38981998 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated TEMPURA
Number of subjects: 24
Study 38982001 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based inflammatory, neuromuscular, and neurovascular biomarkers
Number of subjects: 38
Study 38982001 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based biomarkers
Number of subjects: 38
Study 38982001 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study 38982051 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (PRINCE)
Number of subjects: 0
Study 38982051 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) chemotherapy
Number of subjects: 0
Study 38982328 — intervention group
Group type: EXPERIMENTAL
Intervention: TREAT INTERACT intervention
Number of subjects: 0
Study 38982328 — intervention group
Group type: EXPERIMENTAL
Intervention: mhGAP-IG training for health care personnel
Number of subjects: 0
Study 38982328 — intervention group
Group type: COMPARATOR
Intervention: Control group (schools not receiving intervention)
Number of subjects: 0
Study 38982339 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA) protocol for postdilution continuous veno-venous hemofiltration (CVVH)
Number of subjects: 38
Study 38982360 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised discharge summaries
Number of subjects: 441
Study 38982360 — intervention group
Group type: COMPARATOR
Intervention: Original discharge summaries
Number of subjects: 441